Article
Spliceosome mutations are associated with clinical response in a phase 1b/2 study of the PLK1 inhibitor onvansertib in combination with decitabine in relapsed or refractory acute myeloid leukemia.
Annals of hematology - 1 Nov 2023
Croucher Peter J P, Ridinger Maya, Becker Pamela S, Lin Tara L, Silberman Sandra L, Wang Eunice S, Zeidan Amer M
Abstract excerpt
PLK1 is overexpressed in acute myeloid leukemia (AML). A phase 1b trial of the PLK1 inhibitor onvansertib (ONV) combined with decitabine (DAC) demonstrated initial safety and efficacy in patients with relapsed/refractory (R/R) AML. The current study aimed to identify molecular predictors of response to ONV + DAC in R/R AML patients. A total of 44 R/R AML patients were treated with ONV + DAC and considered...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.